FDA News

FDA Approves Lantus SoloStar A New Prefilled Disposable Insulin Pen For Use With LANTUS In People With Type 1 And Type 2 Diabetes

(April 30, 2007)-- Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) approved Lantus SoloStar, a new prefilled disposable insulin pen for once-daily 24- hour insulin LANTUS (insulin glargine) for the treatment of hyperglycemia in people with type 1 or type 2 diabetes.

The introduction of Lantus SoloStar offers a convenient option for administering once-daily 24-hour LANTUS, the number one prescribed insulin in the world. LANTUS in the Lantus SoloStar pen provides diabetes patients with an alternative to the traditional needle and syringe for insulin therapy. Lantus SoloStar is the only disposable insulin pen that allows patients to administer doses from 1 up to 80 units, in one injection.

"Sanofi-aventis is committed to working with the diabetes community to develop new technologies intended to help make the difficult task of managing diabetes simpler and more convenient," explained Gilles Lhernould, Senior Vice President Industrial Affairs, sanofi-aventis. "Lantus SoloStar is the result of more than 4 years of intensive development and testing with diabetes patients, doctors and nurses," he added.

Share or bookmarklet this web page at: